Have a personal or library account? Click to login
Low Serum Paraoxonase-1 Lactonase and Arylesterase Activities in Obese Children and Adolescents Cover

Low Serum Paraoxonase-1 Lactonase and Arylesterase Activities in Obese Children and Adolescents

Open Access
|Dec 2015

References

  1. 1. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Bio. 1999;19:2214-25. DOI: 10.1161/01. ATV.19.9.2214
  2. 2. Khersonsky O, Tawfik D. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005;44(16):6371-82. DOI: 10.1021/bi047440d10.1021/bi047440d15835926
  3. 3. Ben-David M, Elias M, Filippi JJ, Du-ach E, Silman I, Sussman JL, et al. Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1. J Mol Biol. 2012 May;418(3-4):181–96. DOI: 10.1016/j.jmb.2012.02.04210.1016/j.jmb.2012.02.04222387469
  4. 4. Aviram M, Kaplan M, Rosenblat M, Fuhrman B. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharma. 2005;170:263–300. DOI: 10.1007/3-540-27661-0_910.1007/3-540-27661-0_916596803
  5. 5. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond). 2004 Nov;107(5):435–47. DOI: 10.1042/CS2004018710.1042/CS2004018715265000
  6. 6. Browne RW, Koury ST, Marion S, Wilding G, Muti P, Trevisan M. Accuracy and biological variation of human serum Paraoxonase-1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin Chem. 2007 Feb;53(2):310–7. DOI: 10.1373/clinchem.2006.07455910.1373/clinchem.2006.07455917185369
  7. 7. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983 Nov;35(6):1126-38.
  8. 8. Nguyen SD, Nguyen DH, Park CH, Kim MR, Sok DE. Oxidative inactivation of lactonase activity of purified human Paraoxonase-1(PON1). Biochim Biophys Acta. 2009 Mar;1790(3):155-60. DOI: 10.1016/j. bbagen.2008.11.009
  9. 9. Fuhrman B. Regulation of hepatic paraoxonase-1 expression. J Lipids. 2012; 2012:684010. DOI: 10.1155/2012/68401010.1155/2012/684010332416122548179
  10. 10. She ZG, Chen HZ, Yan Y, Li H, Liu DP. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal. 2012 Mar;16(6):597-632. DOI: 10.1089/ars.2010.377410.1089/ars.2010.3774327005721867409
  11. 11. Koncsos P, Seres I, Harangi M, Illyés I, Józsa L, Gönczi F, et al. Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels. Pediatr Res. 2010 Mar;67(3):309-13. DOI: 10.1203/PDR.0b013e3181c9fb6610.1203/PDR.0b013e3181c9fb6619915520
  12. 12. Seres I, Bajnok L, Harangi M, Sztanek F, Koncsos P, Paragh G. Alteration of PON1 activity in adult and childhood obesity and its relation to adipokine levels. Adv Exp Med Biol. 2010;660:129-42. DOI: 10.1007/978-1-60761-350-3_1210.1007/978-1-60761-350-3_1220221876
  13. 13. Torun E, Gökçe S, Ozgen İT, Aydın S, Cesur Y. Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents. J Pediatr Endocrinol Metab. 2014 Jul;27(7-8):667-75. DOI: 10.1515/jpem-2013-033710.1515/jpem-2013-033724706428
  14. 14. Ferré N, Feliu A, García-Heredia A, Marsillach J, París N, Zaragoza-Jordana M, et al. Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clin Biochem. 2013 Dec;46(18):1830-6. DOI: 10.1016/j.clinbiochem.2013.08.02010.1016/j.clinbiochem.2013.08.02024028901
  15. 15. Conti M, Moran PC, Levillain P, Lemonnier A. Improved fluorimetric determination of malondialdehyde. Clin Chem. 1991 Jul;37(7):1273-5.10.1093/clinchem/37.7.1273
  16. 16. Dobiásová M. AIP-atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006 Jan;52(1):64-71.
  17. 17. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: the R Foundation for Statistical Computing. 2011; ISBN: 3-900051-07-0. Available online at http://www.R-project.org/.
  18. 18. Aslan M, Horoz M, Sabuncu T, Celik H, Selek S. Serum paraoxonase enzyme activity and oxidative stress in obese subjects. Pol Arch Med Wewn. 2011 Jun;121(6):181–6.10.20452/pamw.1051
  19. 19. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005 Mar;90(3):1728–33. DOI: 10.1210/jc.2004-048610.1210/jc.2004-048615613429
  20. 20. Liang KW, Lee WJ, Lee IT, Lee WL, Lin SY, Hsu SL, et al. Persistent elevation of paraoxonase-1 specific enzyme activity after weight reduction in obese non-diabetic men with metabolic syndrome. Clin Chim Acta. 2011 Sep 18;412(19-20):1835-41. DOI: 10.1016/j. cca.2011.06.018
  21. 21. Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol. 2011 Jun;12(2):80-5. DOI: 10.1016/j.ajg.2011.04.00810.1016/j.ajg.2011.04.00821684478
  22. 22. Tabur S, Torun AN, Sabuncu T, Turan MN, Celik H, Ocak AR, et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol. 2010 Mar;162(3):535–41. DOI: 10.1530/EJE-09-073210.1530/EJE-09-073220022940
  23. 23. Krzystek-Korpacka M, Patryn E, Hotowy K, Czapińska E, Majda J, Kustrzeba-Wójcicka I, et al. Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: association with obesity-related inflammation and oxidative stress. Adv Clin Exp Med. 2013 Mar-Apr;22(2):229-36.
  24. 24. Zaki ME, El-Bassyouni H, Kamal S, El-Gammal M, Youness E. Association of serum paraoxonase enzyme activity and oxidative stress markers with dyslipidemia in obese adolescents. Indian J Endocrinol and Metab. 2014 May-Jun;18(3):340-4. DOI: 10.4103/2230-8210.13117310.4103/2230-8210.131173405613224944928
  25. 25. Rupérez AI, López-Guarnido O, Gil F, Olza J, Gil-Campos M, Leis R, et al. Paraoxonase-1 activities and genetic variation in childhood obesity. Br J Nutr. 2013 Nov;110(9):1639-47. DOI: 10.1017/S000711451300196710.1017/S000711451300196723789921
  26. 26. Agirbasli M, Tanrikulu A, Erkus E, Azizy M, Sevim BA, Kaya Z, et al. Serum paraoxonase-1 activity in children: the effects of obesity and insulin resistance. Acta Cardiol. 2014 Dec;69(6):679-85.10.1080/AC.69.6.1000011
  27. 27. Desai S, Baker SS, Liu W, Moya DA, Browne RW, Mastrandrea L, et al. Paraoxonase 1 and oxidative stress in paediatric non-alcoholic steatohepatitis. Liver Int. 2014 Jan;34(1):110-7. DOI: 10.1111/liv.1230810.1111/liv.1230824028323
  28. 28. Huen K, Harley K, Beckman K, Eskenazi B, Holland N. Associations of PON1 and Genetic Ancestry with Obesity in Early Childhood. PLoS ONE. 2013 May;8(5):e62565. DOI: 10.1371/journal.pone.006256510.1371/journal.pone.0062565
  29. 29. Chapman E, Wong CH. A pH sensitive colorimetric assay for the high-throughput screening of enzyme inhibitors and substrates: a case study using kinases. Bioorg Med Chem. 2002 Mar;10(3):551-5. DOI: 10.1016/S0968-0896(01)00306-610.1016/S0968-0896(01)00306-6
  30. 30. James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med. 2004 Dec;37(12):1986-94. DOI: 10.1016/j.freeradbiomed.2004.08.01210.1016/j.freeradbiomed.2004.08.012
  31. 31. Gaidukov L, Tawfik DS. High affinity, stability and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry. 2005 Sep;44(35):11843-54. DOI: 10.1021/bi050862i10.1021/bi050862i
  32. 32. Noto H, Hashimoto Y, Satoh H, Hara M, Iso-o N, Togo M, et al. Exclusive association of Paraoxonase-1with high-density lipoprotein particles in apolipoprotein A-I deficiency. Biochem Biophys Res Commun. 2001 Nov;289(2):395-401. DOI: 10.1006/bbrc.2001.598510.1006/bbrc.2001.5985
  33. 33. Codoner-Franch P, Navarro-Ruiz A, Fernandez-Ferri M, Arilla-Codoner A, Ballester-Asensio E, Valls-Belles V. A matter of fat: insulin resistance and oxidative stress. Pediatr Diabetes. 2012 Aug;13(5):392-9. DOI: 10.1111/j.1399-5448.2011.00847.x10.1111/j.1399-5448.2011.00847.x
  34. 34. Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol. 2000 Aug;11(4):383-8. DOI: 10.1097/00041433-200008000-0000710.1097/00041433-200008000-00007
  35. 35. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999 Apr;26(7-8):892-904. DOI: 10.1016/S0891-5849(98)00272-X10.1016/S0891-5849(98)00272-X
  36. 36. Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoğlu G, Yesilkaya E, et al. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007 Jul;67(1):129-34. DOI: 10.1111/j.1365-2265.2007.02849.x10.1111/j.1365-2265.2007.02849.x17465999
  37. 37. Kelishadi R, Cook SR, Amra B, Adibi A. Factors associated with insulin resistance and nonalcoholic fatty liver disease among youths. Atherosclerosis. 2009 Jun;204(2):538-43. DOI: 10.1016/j.atherosclerosis.2008.09.03410.1016/j.atherosclerosis.2008.09.03419013572
  38. 38. Kelly AS, Jacobs DR, Sinaiko AR, Moran A, Steffen LM, Steinberger J. Relation of Circulating Oxidized LDL to Obesity and Insulin Resistance in Children. Pediatr Diabetes. 2010 Dec;11(8):552-5. DOI: 10.1111/j.1399-5448.2009.00640.x10.1111/j.1399-5448.2009.00640.x289177920102528
  39. 39. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Improved Identification of Patients with Coronary Artery Disease by the Use of New Lipid and Lipoprotein Biomarkers. Am J Cardio. 2006 Mar 1;97(5):640-45. DOI: 10.1016/j.amjcard.2005.09.12310.1016/j.amjcard.2005.09.12316490429
  40. 40. Li R, Oteiza A, Sørensen KK, McCourt P, Olsen R, Smedsrød B, et al. Role of liver sinusoidal endothelial cells and stabilins in elimination of oxidized low-density lipoproteins. Am J Physiol Gastrointest. Liver Physiol. 2011 Jan;300(1):G71-81. DOI: 10.1152/ajpgi.00215.201010.1152/ajpgi.00215.2010302550721030611
DOI: https://doi.org/10.1515/rrlm-2015-0038 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 385 - 396
Submitted on: Jul 14, 2015
Accepted on: Sep 22, 2015
Published on: Dec 30, 2015
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2015 Raluca Sandor, Daniel Leucuta, Eleonora Dronca, Alexandru Niculae, Victoria Cret, Ciprian Silaghi, Soimita Suciu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.